Export 5 results:
Author Title [ Type(Desc)] Year
Filters: Author is MacMillan, Margaret L  [Clear All Filters]
Journal Article
S. G. Holtan, DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, C. S., Arai, S., Lazaryan, A., Newell, L. F., Jagasia, M. H., Pusic, I., Wood, W. A., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Bunworasate, U., Efebera, Y. A., Ferrara, J. L. M., Pidala, J., Howard, A., Wu, J., Bolaños-Meade, J., Ho, V., Alousi, A., Blazar, B. R., Weisdorf, D. J., and MacMillan, M. L., Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802., Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802., Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial., Blood, vol. 135, no. 2, pp. 97-107, 2020.
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT., Blood, vol. 124, no. 8, pp. 1372-7, 2014.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.